To discuss the latest advances, treatments and care strategies to combat heart disease, thousands of cardiologists from around the world descend on Atlanta, Georgia this weekend.
Some of the 30 studies and trials hoping to grab the spotlight at this year's American College of Cardiology four-day meeting shed light on the effectiveness of new products to fight the number one killer in the United States.
"Obviously the buzz word is comparative effectiveness at this conference and in Washington," Temple University School of Medicine cardiothoracic surgeon James McClurken told reporters.
"A lot of these trials are looking at what works with the least side effects and what works most affordably."
The conference comes as the country is roiled by a major debate over reforming the US health care system to expand health insurance access to tens of millions of Americans who have none.
President Barack Obama has escalated his year-long fight to cajole Congress into passing a sweeping health care overhaul, and delayed his departure on a trip to Indonesia and Australia by three days for a last push to get lawmakers to pass the controversial legislation.
Among the featured studies for the gathering of 28,000 heart specialists that begins Saturday is a vast randomized Phase III drug trial conducted in the United States, Canada and Europe.
It compares a non-surgical technique to remedy a deficient heart valve responsible for mitral regurgitation using Abbott's MitraClip to more invasive and more common open heart surgery to repair or replace the valve.